Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Nonimmunosuppressive rotamase inhibitors under study at Guilford for neurological disorders

Oct. 5, 1998

NO-NSAIDs licensed by NicOx to Astra for pain and inflammation

Oct. 2, 1998

Potent analgesic agents from HMR with additional pharmacological effects

Oct. 2, 1998

ADIR claims 2-aminoindanes for CNS disorders involving serotonergic system dysfunction

Oct. 2, 1998

Elan invests in Ligand; Ligand obtains certain rights to Morphelan

Oct. 1, 1998

Japanese investigators design novel class of NMDA receptor channel blocker

Oct. 1, 1998

Agents for dementia a focus of R&D at Sanofi

Oct. 1, 1998

Neurogen compounds interacting with CRF1 receptors for stress-related disorders

Oct. 1, 1998

Chirocaine shows increased safety in obstetric population

Sep. 30, 1998

Guilford prototype PARP inhibitor proves effective in animal models of stroke, heart attack

Sep. 30, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Taiwan biotech looks outward in next phase of growth
BioWorld
Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to...